According to TipRanks.com, Arce is a 4-star analyst with an average return of 13.1% and a 38.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
Arcturus Therapeutics has an analyst consensus of Moderate Sell, with a price target consensus of $40.75, implying a 55.1% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $33.00 price target.
Based on Arcturus Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 million and GAAP net loss of $31.1 million. In comparison, last year the company earned revenue of $2.97 million and had a GAAP net loss of $10.99 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.